{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.004","value":"0.013"},{"groupId":"OG001","spread":"0.003","value":"0.012"},{"groupId":"OG002","spread":"0.003","value":"0.007"},{"groupId":"OG003","spread":"0.002","value":"0.006"},{"groupId":"OG004","spread":"0.002","value":"0.009"},{"groupId":"OG005","spread":"0.004","value":"0.007"},{"groupId":"OG006","spread":"0.004","value":"0.010"},{"groupId":"OG007","spread":"0.003","value":"0.007"},{"groupId":"OG008","spread":"0.004","value":"0.009"},{"groupId":"OG009","spread":"0.003","value":"0.008"},{"groupId":"OG010","spread":"0.003","value":"0.006"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"11"}],"units":"Participants"}],"description":"Clearance is defined as the volume of serum from which study drug was completely removed per unit of time. Blood samples for measurement of serum levels of dalotuzumab were obtained at: pre-dose; pre-end infusion; 0.5, 5, 10, 24, 30 (Q1W only), 48, 96, 168 (Q2W/Q3W only), 336 (Q3W only) hours post infusion. For infusions \\>1 hour in duration, an additional sample was obtained at the mid-point of the infusion.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG000","title":"Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG001","title":"Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG002","title":"Dalotuzumab 5 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG003","title":"Dalotuzumab 10 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.","id":"OG004","title":"Dalotuzumab 10 mg/kg Q1W (20 mg/mL)"},{"description":"Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG005","title":"Dalotuzumab 15 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.","id":"OG006","title":"Dalotuzumab 15 mg/kg Q1W (20 mg/mL)"},{"description":"Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG007","title":"Dalotuzumab 20 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.","id":"OG008","title":"Dalotuzumab 20 mg/kg Q1W (20 mg/mL)"},{"description":"Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion Q2W.","id":"OG009","title":"Dalotuzumab 20 mg/kg Q2W (20 mg/mL)"},{"description":"Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion Q3W.","id":"OG010","title":"Dalotuzumab 30 mg/kg Q3W (20 mg/mL)"}],"paramType":"MEAN","populationDescription":"The population consisted of all evaluable participants who received \\>90% of intended drug volume and had mean serum clearance pharmacokinetic measurements at Baseline and at least once during treatment.","reportingStatus":"POSTED","timeFrame":"Predose; pre-end infusion; 0.5, 5, 10, 24, 30 (Q1W only), 48, 96, 168 (Q2W/Q3W only), 336 (Q3W only) hours post-infusion","title":"Mean Serum Clearance of Dalotuzumab","type":"PRIMARY","unitOfMeasure":"mL/min/kg"}